Literature DB >> 34917871

The inflammasome in heart failure.

Eleonora Mezzaroma1,2, Antonio Abbate2, Stefano Toldo2.   

Abstract

The NACHT, leucine-rich repeat (LRR), and pyrin domain (PYD)-containing protein 3 (NLRP3) inflammasome is a macromolecular structure responsible for the inflammatory response to injury or infection. Several types of heart disease are linked to the activity of the NLRP3 inflammasome and its cytokines, interleukin-1β (IL-1β), and IL-18. Recent pieces of evidence collected from human samples, together with experimental animal models, demonstrate a causative role for the pathogenesis and progression of heart failure (HF). Preclinical research showed that NLRP3 inhibition is a viable strategy to reduce adverse cardiac remodeling and improve left ventricular function in HF. Early phase clinical studies proved to be safe and effective supporting the potential benefit of blocking the NLRP3 inflammasome pathway in patients with HF.

Entities:  

Keywords:  Caspase-1; Heart Failure; Interleukin-18; Interleukin-1β; NLRP3 Inflammasome

Year:  2020        PMID: 34917871      PMCID: PMC8670733          DOI: 10.1016/j.cophys.2020.09.013

Source DB:  PubMed          Journal:  Curr Opin Physiol        ISSN: 2468-8673


  51 in total

Review 1.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

2.  Involvement of NLRP3 inflammasome in CVB3-induced viral myocarditis.

Authors:  Yan Wang; Bo Gao; Sidong Xiong
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-26       Impact factor: 4.733

3.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Am Coll Cardiol       Date:  2017-04-28       Impact factor: 24.094

4.  Association of nucleotide-binding oligomerization domain-like receptor 3 inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy.

Authors:  Beibei Luo; Fan Wang; Bo Li; Zhe Dong; Xiaoman Liu; Cheng Zhang; Fengshuang An
Journal:  Clin Chem Lab Med       Date:  2013-07       Impact factor: 3.694

5.  Cathepsin B-Mediated NLRP3 Inflammasome Formation and Activation in Angiotensin II -Induced Hypertensive Mice: Role of Macrophage Digestion Dysfunction.

Authors:  Dawei Lian; Jieqing Lai; Yanjiao Wu; Lei Wang; Yongjun Chen; Yang Zhang; Krishna M Boini; Yi Huang; Yang Chen
Journal:  Cell Physiol Biochem       Date:  2018-10-25

6.  Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages.

Authors:  Mihai G Netea; Claudia A Nold-Petry; Marcel F Nold; Leo A B Joosten; Bastian Opitz; Jonathan H M van der Meer; Frank L van de Veerdonk; Gerben Ferwerda; Bas Heinhuis; Isabel Devesa; C Joel Funk; Robert J Mason; Bart Jan Kullberg; Anna Rubartelli; Jos W M van der Meer; Charles A Dinarello
Journal:  Blood       Date:  2008-12-22       Impact factor: 22.113

7.  Interleukin-18 mediates interleukin-1-induced cardiac dysfunction.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Laura O'Brien; Carlo Marchetti; Ignacio M Seropian; Norbert F Voelkel; Benjamin W Van Tassell; Charles A Dinarello; Antonio Abbate
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-02-14       Impact factor: 4.733

Review 8.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.

Authors:  Antonio Abbate; Stefano Toldo; Carlo Marchetti; Jordana Kron; Benjamin W Van Tassell; Charles A Dinarello
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

9.  Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure.

Authors:  Benjamin W Van Tassell; Ross A Arena; Stefano Toldo; Eleonora Mezzaroma; Tania Azam; Ignacio M Seropian; Keyur Shah; Justin Canada; Norbert F Voelkel; Charles A Dinarello; Antonio Abbate
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

10.  NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice.

Authors:  Fabiola Marín-Aguilar; Ana V Lechuga-Vieco; Elísabet Alcocer-Gómez; Beatriz Castejón-Vega; Javier Lucas; Carlos Garrido; Alejandro Peralta-Garcia; Antonio J Pérez-Pulido; Alfonso Varela-López; José L Quiles; Bernhard Ryffel; Ignacio Flores; Pedro Bullón; Jesús Ruiz-Cabello; Mario D Cordero
Journal:  Aging Cell       Date:  2019-10-18       Impact factor: 9.304

View more
  3 in total

Review 1.  Targeting the NLRP3 inflammasome in cardiovascular diseases.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Leo F Buckley; Nicola Potere; Marcello Di Nisio; Giuseppe Biondi-Zoccai; Benjamin W Van Tassell; Antonio Abbate
Journal:  Pharmacol Ther       Date:  2021-12-11       Impact factor: 13.400

Review 2.  The Scientific Rationale for the Introduction of Renalase in the Concept of Cardiac Fibrosis.

Authors:  Dijana Stojanovic; Valentina Mitic; Miodrag Stojanovic; Jelena Milenkovic; Aleksandra Ignjatovic; Maja Milojkovic
Journal:  Front Cardiovasc Med       Date:  2022-05-31

Review 3.  Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology.

Authors:  Dobromir Dobrev; Stanley Nattel; Jordi Heijman; Roddy Hiram; Na Li
Journal:  Nat Rev Cardiol       Date:  2022-09-15       Impact factor: 49.421

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.